Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441062 · ClinicalTrials.gov registry record · Phase 2
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
A Phase 2 study of Neuroblastoma and Neuroendocrine Tumors, sponsored by Sue O'Dorisio.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT02441062 is a Phase 2 study of Neuroblastoma and Neuroendocrine Tumors that has completed, run by Sue O'Dorisio. The registered enrollment target is 122 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02441062, a Phase 2 study of Neuroblastoma and Neuroendocrine Tumors, has completed, sponsored by Sue O'Dorisio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.
Conditions Studied
Interventions
- DRUG 68Ga-DOTATOC PET/CT
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2015-09 |
| Est. Completion | 2020-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02441062
The ClinicalTrials.gov registry entry for NCT02441062 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (49% lower). The listed sponsor is Sue O'Dorisio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-DOTATOC PET/CT is the first listed.
NCT02441062 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT02441062 about?
NCT02441062 is a clinical study titled "Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors". Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special proced...
What is the current status of trial NCT02441062?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2015-09. Estimated completion is 2020-01-20.
What conditions does trial NCT02441062 study?
This clinical trial studies the following conditions: Neuroblastoma, Neuroendocrine Tumors, Medulloblastoma, Carcinoid Tumors.
What interventions are being tested in trial NCT02441062?
The interventions under investigation include: 68Ga-DOTATOC PET/CT (DRUG).
Who is sponsoring clinical trial NCT02441062?
This trial is sponsored by Sue O'Dorisio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02441062 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.